Nuformix plc: Unaudited Half Year Results – Significant progress in lead programmes

Significant Progress in Lead Programmes

Cambridge, UK, 20th December 2018: Nuformix (LSE: NFX), the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs, announces the Company’s unaudited results for the six months ended 30 September 2018.

KEY HIGHLIGHTS

  • Pipeline Update:
    • Key development milestone achieved for NXP001 in Oncology Supportive Care triggering payment of £500,000
    • Additional patent filing broadening NXP002 applications in fibrotic conditions
    • Continued growth of pre-clinical portfolio following the development of new drug cocrystals
  • Strengthening Board:
    • Dr Chris Blackwell appointed to the Nuformix Board as a Non-Executive Director
  • Financial Highlights:
    • Reported net loss for the period was £642,633 (2017: £127,546 loss)
    • Operating profit before exceptional items for the reported period was positive at £114,020 (2017: £170,725 loss)

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH